Loading
Vidac Pharma Holding PLC Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest was filed 26 Feb 2026.
Vidac Pharma Holding PLC: what insiders have been doing
Vidac Pharma Holding PLC, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to BaFin. From 18 October 2025 to 18 October 2026, the disclosure feed for Vidac Pharma Holding PLC logged 129 filings by 5 insiders.
Open-market activity splits into 1 purchase totalling €4.8M and 128 sales totalling €1.0M; 1 insider sit on the buying side and 5 insiders on the selling side. Netting one side against the other leaves €3.8M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. Biggest ticket of the year: €4.8M, bought by Herzberg, Dr. Max and made public on 26 February 2026.
Across the 287 companies tracked on its exchange, the median is 5 filings; at 129 filings, this issuer sits above that mark. The full history, which starts in 2025, counts 1 purchase against 128 sales.
The last purchase on record was published on 26 February 2026, which is 233 days ago. The median gap between a trade and its publication by BaFin is 6 days. The legal deadline for notifying a trade is three business days (MAR article 19). A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by BaFin and describes the past, not future prices; it is not investment advice.
Insider Decl.
129
Thresholds
n/a
Buy Volume
€5M
1 ops. · all time
Sell Volume
€1M
128 ops. · all time
Who traded when
BuySaleDr. Max Herzberg1 buy94 sales
Dr Max Herzberg31 sales
Vorstand Max Herzberg3 sales
Vorstands Max Herzberg2 sales
Since the insiders bought
- -51.6%Entry €0.80 · Close 16 Oct 2026 €0.38
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.39
Analyst consensus
Income statement
EBITDA-€1.9M
Net income-€1.9M0.0% margin
Balance sheet & cash
Market cap€21.9M
Total debt€315k
Free Cash Flow-€1.7M
Last declaration on 15 October 2026
Declarations129 total
7,000 shares@ €0.410.013% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-9e1b34a0552e
3,000 shares@ €0.410.0056% mcap0.0% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-0ac0447531ba
4,590.476 shares@ €0.420.0080% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-956ac0dd04f5
3,250 shares@ €0.440.0059% mcap0.0% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-191a83b96dbc
11,250 shares@ €0.440.020% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-905d0084e5b3
8,000 shares@ €0.440.015% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-c6dfaf709797
5,060.976 shares@ €0.410.0086% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-22019504e936
10,000 shares@ €0.400.017% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-118a56363c87
10,000 shares@ €0.410.017% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-fa2cebefc72a
1,000 shares@ €0.430.0018% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-7338755d81a4
366.667 shares@ €0.450.0007% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-fdfd31cbadfd
331.111 shares@ €0.450.0006% mcap0.0% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-e894a9205818
12,500 shares@ €0.430.022% mcap34.6% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-b81ad8de09aa
10,000 shares@ €0.420.017% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-c9ebcf1dc087
20,000 shares@ €0.440.036% mcap0.2% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-b6cb319c90fe
11,000 shares@ €0.450.020% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-e215f7fd8738
7,500 shares@ €0.430.013% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-fca8a1155630
14,000 shares@ €0.410.024% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-a79edd22e089
15,000 shares@ €0.430.027% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-a9cb804a594c
12,611.364 shares@ €0.440.023% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-1791de5dd3d3
2,500 shares@ €0.440.0045% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-022cf4e72e9c
2,104.444 shares@ €0.450.0039% mcap0.4% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-327f973baf34
15,000 shares@ €0.460.029% mcap2.9% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-61753711d3dd
4,000 shares@ €0.460.0076% mcap0.8% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-183d28e48fed
23.522 shares@ €0.460.0000% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-8be701d81aff
25 of 129 declarations
About Vidac Pharma Holding PLC
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company listed on Xetra / Frankfurt (DAX/MDAX/SDAX) in Germany, with a clear focus on oncology and onco-dermatology. Founded in 2012, the company is developing first-in-class therapies built around a scientific approach to cancer metabolism, aiming to address abnormal metabolic processes observed in cancer cells. That positioning gives Vidac a differentiated profile versus many micro-cap healthcare names that rely mainly on reformulations or late-stage licensing plays. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai))
Although the company’s registered address is in London at 20-22 Wenlock Road, London N1 7GU, United Kingdom, its equity-market visibility for continental investors is centered on Germany through Xetra and also Tradegate. For investors in France, Belgium and Switzerland, that means the stock is effectively accessed through the German market infrastructure, even if the operating footprint is international. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai))
Read moreShow less
Vidac’s business model is focused on two main therapeutic areas: oncology and onco-dermatology. Its lead program, VDA-1102, is being developed for indications including actinic keratosis and cutaneous T-cell lymphoma (CTCL). The company also highlights VDA-1275, a next-generation candidate in preclinical development with broader potential in solid tumors. In other words, the investment case is still largely pipeline-driven, with limited diversification but a clearly articulated scientific thesis. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai))
From a competitive standpoint, Vidac operates in a highly contested biotech environment where differentiation depends on the strength of the biology, patent protection, and the quality of clinical translation. The company frames its platform around the Warburg effect and a mechanism intended to restore more normal cellular regulation. That gives it a distinct technological narrative, but it also means the stock remains exposed to the typical risks of clinical-stage biotech: trial outcomes, regulatory uncertainty, and financing needs. ([vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai))
Recent company updates point to continued scientific execution. In 2026, Vidac announced a study to be conducted by PharmaLegacy and reported receipt of a Notice of Allowance from the USPTO for a new patent covering a synthesis pathway for VDA-1102. The company has also disclosed manager transactions under MAR Article 19, which is relevant for German-market investors monitoring insider activity and governance transparency. These developments suggest a business still in the value-creation phase, with catalysts tied to patent progress, clinical development and capital markets access. ([vidacpharma.com](https://vidacpharma.com/en/press-releases?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations